Identification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup>
William E. Holmes(Genesys (United States)), Richard Vandlen(PDL BioPharma (United States)), Helga Raab, H. Michael Shepard, Daniel G. Yansura(Unknown), Robert W. Akita, Wun-Jing Kuang(Genesys (United States)), Nasrin Abadi, John W. Park(University of California, San Francisco), Gail D. Lewis Phillips(Gene Therapy Laboratory), James Lee(Royal Free London NHS Foundation Trust), David V. Goeddel(TiVo (United States)), William L. Wood, Mark X. Sliwkowski(Molecular Oncology (United States)), William J. Henzel
Cited by 964
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k